Premium
Treatment of vaginitis
Author(s) -
Kükner S.,
Ergin T.,
Ciçek N.,
Uǧur M.,
Yeşilyurt H.,
Gökmen O.
Publication year - 1996
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(95)02531-6
Subject(s) - medicine , vaginitis , pessary , miconazole nitrate , bacterial vaginosis , trichomoniasis , metronidazole , miconazole , gynecology , vaginal disease , trichomonas vaginitis , obstetrics , surgery , vagina , antibiotics , dermatology , antifungal , microbiology and biotechnology , biology
Objective: The purpose of this study was to evaluate the efficacy of metronidazole 500 mg and miconazole nitrate 100 mg (Neo‐Penotran ® , Embil Pharmacy Company, Istanbul, Turkey) in the treatment of vaginitis. Method: One hundred patients (mean age 26.5 years, range 18–50) with a clinical diagnosis of vaginitis entered this open, noncomparative study. Each patient inserted a Neo‐Penotran ® pessary twice daily for 14 days. Assessments were carried out at the beginning of the study and 15 and 22 days after the start of therapy. Sudent's t‐test was used for the statistical analysis. Results: Out of 100 patients who were initially recruited to the study, 20 were subsequently excluded, leaving a total of 80 patients (80%) who completed the full course of treatment. Vaginitis was resolved in 75% of cases, it improved in 18% and was unchanged in 7%. The success rate for the treatment of trichomoniasis was 80%, 93.4% for bacterial vaginosis and 84.4% for candidal vaginitis. Conclusion: Neo‐Penotran ® pessaries represent a novel and effective formulation for the treatment of common types of vaginitis and this pessary may also be of particular value in the treatment of resistant or recurrent vaginitis.